Randomized Comparison of Primary Percutaneous Coronary Intervention With Combined Proximal Embolic Protection and Thrombus Aspiration Versus Primary Percutaneous Coronary Intervention Alone in ST-Segment Elevation Myocardial Infarction The PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-Elevation) Study by Haeck, Joost D.E. et al.
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935rimary percutaneous coronary intervention (PCI) has been
hown to be the superior treatment for ST-segment eleva-
ion myocardial infarction (STEMI) and effectively restores
erfusion of the infarct-related artery (1). Despite its value,
rimary PCI using balloons and stents alone may dislodge
therothrombotic material adherent to the ruptured plaque,
ausing microvascular obstruction and limiting myocardial
alvage. Embolization of atherothrombotic material during
rimary PCI is considered an important determinant of
icrovascular obstruction and is associated with impaired
T-segment resolution, increased infarct size, reduced re-
overy of ventricular function, and a 5-fold increase in
-year mortality (2–6). Most randomized trials of thrombus
spiration catheters and distal embolic protection devices
id not show a treatment benefit, thereby not supporting
he use of any embolic protection device or thrombus
spiration catheter in the setting of STEMI (7–15). Re-
ently, the TAPAS (Thrombus Aspiration during Percuta-
eous coronary intervention in Acute myocardial infarction
tudy) showed that thrombus aspiration before stenting of
he infarct-related artery resulted in improved myocardial
lush grade (MBG) and clinical outcome 1-year after
rimary PCI (16,17).
The Proxis device (St. Jude Medical, St. Paul, Minne-
ota) (Fig. 1) is a novel system of combined proximal
mbolic protection and thrombus aspiration. In a registry of
72 patients, we showed that the Proxis system was feasible
nd safe in the setting of primary PCI in patients with
TEMI. The results demonstrated good angiographic out-
omes, excellent ST-segment resolution, and low 1-year
ortality (18). On the basis of these findings, the random-
zed, controlled PREPARE (Proximal Embolic Protection
n Acute Myocardial Infarction and Resolution of ST-
levation) trial was designed to evaluate the effectiveness of
ombined proximal embolic protection with thrombus as-
iration during mechanical reperfusion therapy in STEMI.
ethods
atient selection and treatment. The PREPARE trial is an
nvestigator-initiated, randomized, open trial with blinded
valuation of end points, in which 2 hospitals with 24/7
oronary intervention facilities in the Netherlands (Aca-
emic Medical Center, University of Amsterdam, Amster-
am, the Netherlands) and in Canada (Institut de Cardi-
logie de Montréal, Montréal, Canada) participated. The
nstitutional review board of both hospitals approved the
tudy. Written informed consent was obtained from all
atients.
Patients were eligible for the trial if they had symptoms of
yocardial infarction 6 h after onset, electrocardiographic
vidence of persistent ST-segment elevation of at least 200
V in 2 or more contiguous leads. Exclusion criteria werendividuals younger than 18 years of age, contraindications Po the use of glycoprotein IIb/IIIa receptor antagonists,
oexistent condition associated with a limited life expect-
ncy, prior coronary artery bypass grafting or lytics, recur-
ence of myocardial infarction in the same myocardial area,
n electrocardiogram (ECG) unsuitable for ST-segment
esolution evaluation (left bundle branch block, ventricular
acemaker, and atrial fibrillation). Patients were included
fter the first angiogram provided Thrombolysis In Myo-
ardial Infarction (TIMI) flow grade 0 to 1 and a coronary
natomy suitable for treatment with the Proxis system.
atients were not included if any of the following applied:
eft main occlusion, left main stenosis of more than 30%,
eavy proximal calcifications, a small infarct-related artery
2.5 mm in diameter), and a proximal location of the
esion leading to an insufficient “landing zone” for the Proxis
ystem (generally 10 to 12 mm). Informed consent was
btained after suitability of coronary anatomy of the patient
or the treatment with the Proxis system had been estab-
ished. Patients who consented were subsequently random-
zed 1:1 to a strategy of primary
CI with combined embolic
rotection and thrombus aspira-
ion or to primary PCI alone.
The Proxis system was used
n patients randomized to pri-
ary PCI with combined em-
olic protection and thrombus
spiration. The Proxis system
s a single-operator full-length
exible catheter (6- or 7-F
uiding catheter compatible)
nd based on a carbon dioxide
as (CO2) inflation system. It
as deployed proximal to the
arget lesion before crossing.
nflation of the sealing balloon suspends antegrade flow
uring the period of lesion intervention. Stagnated blood
nd emboli liberated after each lesion intervention were
etrieved by gentle aspiration. Crossing of the coronary
cclusion with the wire, balloon dilation, and stent place-
ent was performed through the Proxis system and carried
ut under full proximal blockade of the vessel. Aspiration
nd embolic protection by temporary proximal vessel occlu-
ion were repeated during each step of the PCI procedure
18).
Primary PCI was performed in a standard manner with
pproved wires, balloons, and stents in patients randomized
o primary PCI alone. All patients received 300 mg of
spirin, clopidogrel (600 mg followed by 75 mg/24 h),
nfractionated heparin (70 U/kg) before PCI. Use of
lycoprotein IIb/IIIa receptor antagonists was left to oper-
tor discretion. After the procedure, patients were trans-
erred to the coronary care unit. Standard therapies after
Abbreviations
and Acronyms
CI  confidence interval
CK-MB  creatine
phosphokinase myocardial
band isoenzyme
MACCE  major adverse
cardiac and cerebral events
MBG  myocardial blush
grade
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionCI included aspirin (at least 80 mg daily), clopidogrel (75
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936g daily), beta-blockers, lipid-lowering agents, and
ngiotensin-converting enzyme inhibitors or angiotensin II
eceptor blockers, according to European Society of Cardi-
logy guidelines (19). Stabilized patients from referring
ospitals were transferred back after a minimum of 6 h.
ata collection. Continuous digital 12-lead ECG/Holter
onitoring (Northeast Monitoring 180, Natick, Massa-
husetts) for ST-segment analysis was started on arrival at
he catheterization laboratory before PCI. Continuous
CG monitoring was continued a minimum of 6 h after
CI. Continuously updated ST-segment resolution analysis
as performed by a central core laboratory (eECG Core
aboratory, Duke Clinical Research Institute/Duke Univer-
ity Medical Center, Durham, North Carolina) using pre-
iously published methodology (20,21). In brief, ST-
egment levels were measured 60 ms after the J-point in the
ost abnormal lead. ST-segment recovery was determined
ver serial time points by comparing ECGs recorded at each
pecified time interval with the most abnormal “peak” ECG
n the data recorded between study enrollment and arrival in
he catheterization laboratory. The 12-lead summated ST-
egment deviation versus time trend curves were used to
alculate ST-segment injury curve areas. Changes during
Figure 1. The Proxis Embolic Protection System
The Proxis Embolic Protection System in a native coronary artery.he interventional procedure were excluded from analysis. Tll ST-segment recovery end points were read blinded to
ny treatment assignment or clinical information.
After the PCI procedure, a coronary angiogram was
btained, and TIMI-graded coronary flow, MBG, and
ngiographic signs of distal embolization were estimated as
reviously described (5,22,23). Two experienced investiga-
ors (K.T.K., R.J.dW.), blinded to all other data, assessed all
ngiograms. In case of any discrepancies, a third experi-
nced investigator (J.P.S.H.) determined the angiographic
arameters. Cardiac creatine phosphokinase-myocardial
and isoenzyme (CK-MB) levels were measured at admis-
ion, and after 5, 7, 10, 12, 18, and 24 h. Retrieved debris
efore and after target lesion intervention was collected in
eparate filters. Aspirated material was assessed by inspec-
ion and histopathologic analysis of the filter content. A
athologist (A.C.VdW.), blinded to the angiographic find-
ngs and the result of PCI, performed the histopathologic
nalyses. Information about clinical events was obtained
rom hospital records and from telephone interviews with
he study participants at 30 days.
nd point deﬁnitions. The primary end point of the study
as the occurrence of complete (70%) resolution of
T-segment elevation 60 min after last contrast injection.
omplete ST-segment resolution (dichotomous) was de-
ned as a reduction of at least 70% of the ST-segment
eviation of the most deviated lead relative to the peak
T-segment deviation before PCI. Secondary ECG end
oints were the occurrence of complete (70%) resolution
f ST-segment elevation immediately after PCI (at the time
f last contrast injection) and at 30, 90, and 120 min after
ast contrast injection; percentage of ST-segment elevation
esolution (continuous) immediately after PCI and at 30,
0, 90, and 120 min after last contrast injection; and ST-
egment curve area. Percentage of ST-segment elevation
esolution was defined as the percentage change between the
ost abnormal lead in the most abnormal ECG in the
ecording session before the PCI (the “peak” ECG) and the
T-segment level in that same lead at each of the designated
ime points (immediate end PCI, 30, 60, 90, and 120 min
fter last contrast injection). ST-segment curve area was
efined as the area under the summated 12-lead absolute
T-segment deviation versus time trend curve from the last
ontrast injection to 3 h after PCI, reported as V/min.
ngiographic end points were TIMI-graded coronary flow,
BG, and the presence of angiographic signs of distal
mbolization (5,22). The enzymatic end point was infarct
ize measured by a biochemical biomarker of myocardial
ecrosis (CK-MB). Clinical end points were overall major
dverse cardiac and cerebral events (MACCE). Overall
ACCE included death, spontaneous or procedural myo-
ardial infarction, stroke, and percutaneous or surgical target
essel revascularization. All deaths were cardiovascular un-
ess an unequivocal noncardiac cause could be identified.
he myocardial infarctions and target vessel revasculariza-
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937ions were classified according to standardized definitions of
he Academic Research Consortium (24). Stroke was de-
ned as a new focal neurologic deficit of vascular origin
asting more than 24 h. Stroke was further classified as the
esult of intracranial hemorrhage, ischemia (if a computed
omography or MRI scan was available), or uncertain cause.
ll suspected clinical events were adjudicated by a blinded
ritical events adjudication committee.
tatistical analyses. The main clinical analysis consists of a
ingle comparison between the treatment groups of the
ercentage of patients with more than 70% resolution of the
T-segment elevation at the time of last contrast injection.
e designed our study to have a power of beta  80% to
etect an improvement in percentage of patients with
omplete (70%) ST-segment resolution by 15% with a
evel of significance of alpha 0.05. These assumptions
ielded a sample size of 140 patients in each treatment arm.
All data were analyzed on an intention-to-treat basis.
iscrete variables are reported as counts and continuous
ariables, mean  SD, or median and interquartile range.
hi-square and Fisher exact probability test were used to
est equality of the event rates. The 95% confidence interval
CI) for the rate difference is calculated via the exact
ethod. Data are expressed as mean  SD or as medians,
henever appropriate. Student t test or Mann-Whitney U
est were used accordingly. For all statistical analyses, we
sed the SPSS software package, version 16.0 (SPSS Inc.,
hicago, Illinois). A value of p  0.05 in the 2-tailed test
as regarded as significant. Because the study was not
owered for clinical outcomes, the event rates are presented
or descriptive purposes only, and no statistical comparisons
ere done.
esults
atients and treatment. Between March 1, 2006, and June
7, 2008, 284 STEMI patients, at 2 centers in the Neth-
rlands and Canada, were randomized to receive either
rimary PCI with combined proximal embolic protection
nd thrombus aspiration (n 141) or primary PCI alone (n
143). Randomization flow is shown in Figure 2. Baseline
emographic and angiographic characteristics were well
atched between the 2 randomized cohorts, except for a
igher incidence of current smoking in the control group
nd an older population in the Proxis-treated group (Table
). Almost all patients had a complete occlusion of the
nfarct-related artery at the first angiogram: there was a
IMI flow grade of 0 to 1 in 274 of the 281 patients (98%).
rocedural results. The procedural results are summarized
n Table 2. The Proxis system was adequately positioned in
32 of 141 patients (94%). As shown in Table 2, combined
roximal embolic protection and thrombus aspiration re-
ulted in a 3-min delay in arterial puncture to first balloon
nflation compared with the control group. Direct stenting ias performed in a minority of patients (15%). No emer-
ency coronary artery bypass graft surgery was required, and
here were no intraprocedural deaths or strokes. Further-
ore, no dissection or vessel trauma at the site where the
roxis system had been inflated was observed.
T-segment recovery. Complete ST-segment resolution at
0 min after last contrast injection occurred in 101 of the
26 patients (80%) in the Proxis arm and in 72% (93 of 129)
f patients in the control group (absolute difference, 8.1%,
5% CI: 2.4% to 18.6%; p  0.14). Complete ST-
egment resolution at the end of PCI occurred in 85 of 129
atients (66%) receiving combined proximal embolic pro-
ection and thrombus aspiration and in 67 of 135 patients
50%) in the control group (absolute difference, 16.3%; 95%
I: 4.3% to 28.2%; p  0.009), with a median percent
T-segment resolution of 79% versus 69% respectively (p 
.015) as shown in Table 3 and no evidence of heteroge-
eity. The difference between the 2 groups evanesced over
ime, as shown in Figure 3; however, the overall ST-
egment curve area (0 to 3 h after primary PCI) was still
ignificantly lower in the Proxis arm versus the control arm
5,192 V/min vs. 6,250 V/min, p  0.037) (Table 3).
aster and more complete ST-segment resolution with the
roxis system was observed in a host of subgroups evaluated,
284 patients randomized
143 patients assigned to
undergo primary PCI 
alone
Secondary end points
128 included in analysis of
ST-segment curve area
141 included in analysis of
final TIMI-graded flow
140 included in analysis of
MBG
139 included in analysis of
distal embolization
92 included in analysis of 
enzymatic infarct size
141 included in analysis of
30 days MACCE
141 patients assigned to
undergo PCI with Proxis
Primary end point
126 included in analysis of
ST-segment resolution
after PCI
Primary end point
129 included in analysis of
ST-segment resolution
after PCI
Secondary end points
126 included in analysis of
ST-segment curve area
143 included in analysis of
final TIMI-graded flow
141 included in analysis of
MBG
141 included in analysis of
distal embolization
83 included in analysis of 
enzymatic infarct size
143 included in analysis of
30 days MACCE
Figure 2. Randomization Flow
MACCE  major adverse cardiac or cerebral events; MBG  myocardial
blush grade; PCI  percutaneous coronary intervention; TIMI  Thromboly-
sis In Myocardial Infarction.ncluding subgroups according to infarct-related artery and
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938he use of glycoprotein IIb/IIIa receptor antagonists. The
bsolute differences varied between 9.8% and 28.6% (Table 4).
ngiographic, enzymatic, histopathologic, and 30-day clinical
utcomes. Combined proximal embolic protection and
hrombus aspiration tended to improve post-procedural
IMI flow grade (p  0.06). No statistical difference in
BG was observed. The rates of angiographically docu-
ented signs of distal embolization were slightly less
requent and infarct size measured by peak of CK-MB was
maller in the Proxis-treated patients. But none of these
Table 1. Baseline Characteristics of the Patients
PCI With
(n  1
Age, yrs 62
Male sex 112 (80%
History of
Diabetes mellitus* 17 (12%
Hypertension† 44 (31%
Hypercholesterolemia† 29 (21%
Myocardial infarction 8 (6%
PCI 9 (6%
Cerebrovascular disease 8 (6%
Cardiovascular disease in family 49 (35%
Smoking 21 (15%
Current smoking 70 (50%
Pre-infarction angina 10 (7%
SBP, mm Hg 135
DBP, mm Hg 77
Heart rate, beats/min 72
Maximal ST-segment deviation, V 468 (306
Number of diseased vessels
1 95 (67%
2 40 (28%
3 6 (4%
Infarct-related vessel
Left anterior descending artery 41 (29%
Left circumﬂex artery 14 (10%
Right coronary artery 86 (61%
Baseline TIMI ﬂow grade
0 127 (90%
1 12 (9%
2 2 (1%
Visible thrombus 107 (76%
Lesion type
B1 21 (15%
B2 88 (62%
C 32 (23%
Data are expressed as mean SD, n (%), or median (interquartile rang
the percutaneous coronary intervention (PCI) with Proxis group and
diagnosed before admission and managed with diet, oral hypoglycem
as that requiring prescription medication. Lesion type was classified a
Cardiology and the American Heart Association.
DBP diastolic blood pressure; SBP systolic blood pressure; TIMIifferences reached statistically significance (Table 5). aDebris was confirmed on pathology in 84 of the 112
atients (75%). In 73 of the 84 patients (87%), debris was
xtracted before dilation or stent placement. In 29 of the 84
atients (35%), debris was aspired before and after target
esion intervention and in 11 of the 84 patients (13%) only
fter target lesion intervention. Histopathologic analysis of
he filter content showed in 42 of the 84 patients (50%) only
hrombus, in 41 of the 84 patients (49%) thrombus and
laque components, and in only 1 patient (1%) only plaque
omponents. No difference in the composite of debris before
Primary PCI Alone
(n  143) p Value
59 11 0.03
114 (80%) 0.95
9 (6%) 0.09
33 (23%) 0.12
19 (13%) 0.10
13 (9%) 0.27
10 (7%) 0.84
6 (4%) 0.57
54 (38%) 0.60
18 (13%) 0.56
93 (65%) 0.01
7 (5%) 0.44
129 26 0.08
77 16 0.93
75 20 0.32
572 (337–703) 0.52
0.68
99 (69%)
31 (22%)
13 (9%)
0.86
42 (29%)
15 (11%)
86 (60%)
0.52
127 (89%)
11 (8%)
5 (4%)
95 (66%) 0.08
0.29
22 (15%)
99 (69%)
22 (15%)
for maximal ST-segment deviation were available for 131 subjects in
jects in the primary PCI alone group. *Diabetes was defined as that
ts, or insulin; †hypertension and hypercholesterolemia were defined
g to the Lesion Complexity Classification of the American College of
mbolysis In Myocardial Infarction.Proxis
41)
11
)
)
)
)
)
)
)
)
)
)
)
29
17
18
–781)
)
)
)
)
)
)
)
)
)
)
)
)
)
e). Data
136 sub
ic agen
ccordinnd after target lesion intervention was observed.
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939As shown in Table 6, overall MACCE occurred with
imilar frequency with or without combined proximal em-
olic protection and thrombus aspiration (4% vs. 7%). Two
atients died in each treatment group of progressive heart
ailure. None of the repeat angiograms showed evidence of
(re)stenotic lesion or complication at the site where the
roxis system had been inflated.
iscussion
he PREPARE trial is the first proof-of-concept trial to
est the effectiveness of primary PCI with combined prox-
mal embolic protection and thrombus aspiration compared
ith primary PCI.
The difference in the pre-specified primary end point,
0% versus 72% of patients with complete (70%) ST-
egment resolution at 60 min, did not reach statistical
ignificance. Yet, the intention-to-treat analysis showed a
Table 2. Procedural Results
PCI Wi
(n 
Procedural success 141 (1
Direct stenting 15 (1
Balloon angioplasty 4 (3
Proxis placed 132 (9
Length of stented segment, mm 25
Diameter of stented segment, mm 3.5
Additional thrombus aspiration 8 (6
Left ventricular support 6 (4
GP IIb/IIIa receptor antagonists 61 (4
Symptom onset to balloon, min 170 (1
Arterial puncture to balloon, min 17 (1
Total procedure time, min 45 (3
Cath lab call to arterial puncture, min 46 (3
Data are expressed as n (%), mean SD, or median (interquartile rang
for 133 subjects in the percutaneous coronary intervention (PCI) with
GP glycoprotein.
Table 3. Continuous ST-Segment Recovery Paramete
PCI With P
(n  14
ST-segment resolution, %
Immediate 79 (63–98
At 30 min 83 (70–97
At 60 min 88 (72–10
At 90 min 87 (75–99
At 120 min 86 (72–99
ST-segment curve area,* V/min 5,192 (3,793
Data are expressed as median (interquartile range). Data for immediat
group and 135 subjects in the primary percutaneous coronary interven
60min, 126 and 129 subjects; for at 90 min, 124 and 131 subjects; for asubjects. *Area under the ST-segment deviation versus time trend curve is froignificantly higher immediate ST-segment resolution in
avor of Proxis-treated patients and a significant reduction
f overall injury current over time. While ST-segment
ecovery parameters are ultimately surrogate electrocardio-
raphic biomarkers, they reflect intensity and duration of
yocardial ischemia and have consistently been associated
ith infarct size, ejection fraction, and mortality in patients
ith myocardial infarction (2–4,25). Although the primary
nd point of 70% ST-segment resolution at 60 min and
mportant secondary end points, such as MBG, were not
tatistically significant different between the 2 groups, there
as a measurable effect very early with reperfusion that then
quilibrated across groups over time. Mechanistically, this
ery early measurable difference in ST-segment recovery is
onceptually consistent with prevention of distal emboliza-
ion. Although the difference in ST-segment resolution
ith the Proxis system was transient, improved microcircu-
atory reperfusion within the first hour after restoration of
xis Primary PCI Alone
(n  143) p Value
141 (99%)
27 (19%) 0.05
8 (6%) 0.25
—
24 10 0.08
3.5 0.4 0.21
8 (6%) 0.97
5 (4%) 0.74
50 (35%) 0.15
) 153 (126–212) 0.07
14 (10–18) 0.01
31 (25–40) 0.01
45 (35–53) 0.37
for catheterization laboratory call to arterial puncture were available
roup and 139 subjects in the primary PCI alone group.
Primary PCI Alone
(n  143) p Value
69 (43–92) 0.015
78 (63–93) 0.13
84 (67–97) 0.15
85 (67–98) 0.45
87 (73–97) 0.74
) 6,250 (4,221–9,186) 0.037
ment resolution were available for 129 subjects in the PCI with Proxis
I) alone group; for at 30min, 130 and 135 subjects, respectively; for at
in, 126 and 131 subjects; and for ST-segment curve area, 128 and 126th Pro
141)
00%)
1%)
%)
4%)
 10
 0.4
%)
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3%)
32–234
3–23)
6–58)
7–56)
e). Data
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roxis
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PCI  percutaneous coronary intervention; STR  ST-segment resolution.
CI confidence interval; other abbreviations as in Table 2.
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940picardial flow may translate into a clinically relevant reduc-
ion in infarct size and clinical outcomes, although the
urrent study was underpowered to answer this question
efinitively.
Multiple explanations may be proposed as to why com-
ined proximal embolic protection and thrombus aspiration
eads to enhance myocardial reperfusion as observed by early
T-segment recovery. In contrast to distal protection de-
ices and manual thrombus aspiration devices, the Proxis
ystem provides embolic protection before wire crossing of
he thrombotic coronary occlusion. Inflation of the sealing
alloon suspends antegrade flow in the infarct-related artery
uring every manipulation and engagement of the throm-
otic occlusive lesion with wires, balloons, and also later
ith stents. Hence, the Proxis system prevents both embo-
ization during lesion crossing and protects the distal side
ranches of the infarct-related artery. In the PREPARE
rial, debris was extracted in 48% of patients at the time of
arget lesion stent placement, which likely provides addi-
ional protection against distal embolization. In addition to
mbolic protection and thrombus aspiration, the intracoro-
ary evacuation of biologically active inflammatory media-
ors produced at the site of the plaque could contribute to
mprovement of microcirculatory flow (26). Pathophysio-
ogical mechanisms that involve thrombus composition (i.e.,
latelets, inflammatory cells, and plaque components), myo-
ardial perfusion, and microvascular obstruction are still
Last Contrast Injection
lete ST-Segment Resolution
p Value
CI Alone
135) Absolute Difference (95% CI)
(50%) 16.3 (4.3 to 28.2) 0.009
(18%) 24.6 (4.2 to 45.0) 0.03
(63%) 12.7 (0.6 to 26.0) 0.08
(40%) 28.6 (7.8 to 49.5) 0.01
(55%) 9.8 (4.8 to 24.4) 0.22
(50%) 15.3 (1.2 to 29.4) 0.04
(49%) 18.9 (4.1 to 41.9) 0.15
(49%) 18.7 (3.0 to 34.4) 0.02
(50%) 13.3 (5.5 to 32.2) 0.18
(28%) 27.5 (7.8 to 47.2) 0.008
(61%) 12.1 (2.4 to 26.5) 0.14
(53%) 21.8 (6.1 to 37.5) 0.007
(44%) 14.8 (4.8 to 33.0) 0.1830 60 90 120
40
50
60
70
80
90
85
129
96
130
101
126
100 98
124 126
67
135
87
135
93
129
97 100
131 131
Proxis system
Control
P-value 0.009 0.11 0.14 0.23 0.88
Last
contrast
Figure 3. Rates of Complete (>70%) ST-Segment Resolution at Different
Time Periods After Primary PCI With Proxis System or AloneTable 4. Subgroup Analyses for the Complete ST-Segment Resolution at Time of
Rate of Comp
PCI With Proxis
(n  129)
Primary P
(n 
All patients 85/129 (66%) 67/135
Infarct-related artery
Anterior 16/38 (42%) 7/40
Nonanterior 69/91 (76%) 60/95
Lesion
Proximal 29/42 (69%) 19/47
Nonproximal 56/87 (64%) 48/88
Baseline thrombus
Yes 64/98 (65%) 46/92
No 21/31 (68%) 21/43
Symptom onset to balloon, h
3 47/69 (68%) 43/87
3 38/60 (63%) 24/48
Use of GP IIb/IIIa antagonists
Yes 29/52 (56%) 13/46
No 56/77 (73%) 54/89
Current smoking
Yes 47/63 (75%) 47/89
No 38/66 (58%) 20/46
Data are expressed as n (%).
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941nknown and need further investigation (27). Another
nteresting although unproven explanation for our results
ay be ischemic post-conditioning (28). The sequential and
epetitive inflations of the sealing balloon of the Proxis
ystem may have prevented reperfusion injury by inducing
epetitive transient episodes of ischemia at the time of
yocardial reperfusion.
The success of this randomized multicenter study was
nhanced by the fact that technical success rates with the
roxis system in primary PCI were high. In 94% of the
ases, combined proximal embolic protection and thrombus
spiration were performed. Atheromatous and/or throm-
otic debris was retrieved in 75% of patients, similar to the
7% rate of histologically confirmed material demonstrated
n our registry. The use of the Proxis system resulted in only
3-min delay in arterial puncture to first balloon inflation
ime.
Our findings support the beneficial effect of the Proxis
ystem. In addition, the favorable outcome in immediate
T-segment resolution occurred despite a lower frequency
f direct stenting with the Proxis system, which is associated
ith reduction of microvascular injury (29). Notably, the
ercentage of patients with complete ST-segment resolu-
ion in the control arm of our study was comparable at all
ime points to that in the treatment and control arms of the
MERALD (Enhanced Myocardial Efficacy and Recovery
y Aspiration of Liberated Debris) trial (15). In that study,
T-segment resolution over time was superimposable for
he control and distal protection arms.
The PROXIMAL (Proximal Protection During Saphe-
ous Vein Graft Intervention) trial recently demonstrated
quivalent effectiveness of the Proxis system compared with
istal embolic protection in PCI of saphenous vein grafts
30). The PREPARE trial identifies another application of
Table 5. Angiographic Outcomes and Infarct Size
PCI W
(n
TIMI ﬂow grade
0–1 0
2 10
3 131
Myocardial blush grade
0–1 5
2 22
3 113
Angiographic signs of distal embolization 14
Infarct size by peak CK-MB, g/l* 204
Data are expressed as n (%) or median (interquartile range). Data for m
group and 141 subjects in the PCI alone group; for angiographic signs
by peak creatine kinase-myocardial band (CK-MB), 92 and 83 subjects
Amsterdam and 5.0 g/l for Institut de Cardiologie de Montréal, respe
Abbreviations as in Table 1.ombined proximal embolic protection and thrombus aspi-ation. Our study was designed to include a selection of
TEMI patients (i.e., TIMI flow grade 0 to 1, 200 V
T-segment elevation). Since the Proxis system demon-
trated the ability to aspirate atherothrombotic material
fter target lesion intervention, other subset of patients, in
articular myocardial infarction patients with “spontane-
usly reperfused arteries,” may also benefit from combined
roximal embolic protection and thrombus aspiration,
hich were not included in our trial. Larger prospective
andomized trials with relevant clinical end points are
eeded to demonstrate an effect of proximal protection with
he Proxis system on patient outcome in primary PCI.
tudy limitations. First, the PREPARE trial was under-
owered to detect differences in clinical events. The study
easured surrogate end points, which may provide insight
nto a mechanistic impact that may translate into clinical
roxis
1)
Primary PCI Alone
(n  143) p Value
0.06
3 (2%)
15 (11%)
125 (87%)
0.93
9 (6%)
15 (11%)
117 (83%)
20 (14%) 0.36
78) 246 (154–413) 0.22
ial blush grade were available for 140 subjects in the PCI with Proxis
l embolization, 139 and 141 subjects, respectively; and for infarct size
K-MB upper limit of normal is 6.5 g/l for Academic Medical Center
Table 6. Clinical End Points 30 Days
PCI With Proxis
(n  141)
Primary PCI Alone
(n  143)
Death 2 2
Spontaneous myocardial infarction 1 2
Procedural myocardial infarction* 1 1
Urgent percutaneous TLR 2 3
Urgent percutaneous TVR 2 4
Surgical TVR 1 2
Acute stent closure 2 2
Stroke 0 1
Overall MACCE 6 10
Percutaneous non-TVR 9 8
Surgical non-TVR 0 0
Data are expressed as number of patients. *Myocardial infarction related to additional percuta-
neous coronary intervention (PCI).
MACCE  major adverse cardiac or cerebral events; TLR  target lesion revascularization;ith P
 14
(0%)
(7%)
(93%)
(4%)
(16%)
(81%)
(10%)
(136–3
yocard
of dista
. *The C
ctively.TVR target vessel revascularization.
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942enefit. Second, our study was conducted in 2 high-volume
enters with experienced operators, proficient with the
roxis system. Therefore, the results may not be extrapo-
ated to settings with less experienced operators and/or to
ow-volume centers. Third, the results of our study may not
e applicable to other patient and lesion subtypes. Mainly
ue to the necessity of a “landing zone” for the Proxis system
10 to 12 mm), patients with a myocardial infarction
elated to an ostial left anterior descending coronary artery
ere excluded. The slight preponderance of myocardial
nfarctions related to the right coronary artery in our trial
ay be due to this necessity for a “landing zone.” Finally,
ecause most patients were referred from other non-PCI
ospitals and were transferred back after a relatively short
bservation time, CK-MB values were complete in only
2% of the patients.
onclusions
here was no significant difference in complete (70%)
T-segment resolution at 60 min in this proof-of-concept
tudy. However, we observed a significant difference in
mmediate complete ST-segment resolution in Proxis-
reated patients, better ST-resolution at later time points,
nd a reduction of ECG injury current over time, compared
ith control patients. The results of the PREPARE trial
uggest that primary PCI with combined proximal embolic
rotection and thrombus aspiration may lead to better
mmediate microvascular flow in STEMI patients.
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